


Electronic supplementary material



ESM Fig. 1 Patients reaching (a) American Diabetes Association [1]; and (b) American Association of Clinical Endocrinologists [2] targets for glycaemic control (last observation carried forward, intention-to-treat population). * Significant vs glargine ($p=0.0001$) and placebo ($p<0.0001$); # significant vs glargine ($p=0.0139$) and placebo ($p<0.0001$)

References

1. American Diabetes Association (2008) Standards of medical care in diabetes – 2008. *Diabetes Care* 31(Suppl 1):S12–S54.
2. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force (2007) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. *Endocr Pract* 13(Suppl 1): 1–66.